Scarica l'app Stockscreener
0.6082
2.58%
-0.0161
Dopo l'orario di chiusura:
.61
0.0018
+0.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.6243
Aprire:
$0.628
Volume 24 ore:
928.37K
Relative Volume:
0.37
Capitalizzazione di mercato:
$24.02M
Reddito:
$875.70K
Utile/perdita netta:
$-39.57M
Rapporto P/E:
-0.4531
EPS:
-1.3423
Flusso di cassa netto:
$-33.65M
1 W Prestazione:
-5.73%
1M Prestazione:
-16.50%
6M Prestazione:
-80.25%
1 anno Prestazione:
-78.88%
Intervallo 1D:
$0.6001
$0.63
Intervallo di 1 settimana:
$0.6001
$0.6808
Portata 52W:
$0.6001
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Nome
Vistagen Therapeutics Inc
Settore
Industria
Telefono
650-577-3600
Indirizzo
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Confronta VTGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.6082 | 24.66M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-17 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Downgrade | Maxim Group | Buy → Hold |
| 2025-12-17 | Downgrade | Stifel | Buy → Hold |
| 2025-12-17 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-07 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-07-22 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Iniziato | Robert W. Baird | Outperform |
| 2021-02-18 | Iniziato | Jefferies | Buy |
| 2021-01-04 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Iniziato | Maxim Group | Buy |
| 2018-02-08 | Reiterato | Chardan Capital Markets | Buy |
| 2017-03-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER - GlobeNewswire
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline - ACCESS Newswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTGN Should Contact Robbins LLP for Information About Leading the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit - The AI Journal
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Vistagen - GlobeNewswire
2026-01-26 | VTGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:VTGN | Press Release - Stockhouse
VISTAGEN CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit - GlobeNewswire Inc.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionVTGN - TMX Newsfile
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Vistagen - GlobeNewswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit - Barchart.com
ROSEN, A LEADING LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionVTGN - marketscreener.com
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – - GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics - Barchart.com
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors - GlobeNewswire
Vistagen Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Vistagen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026VTGN - Barchart.com
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics - marketscreener.com
Vistagen Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
VTGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - GuruFocus
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen - GlobeNewswire
Vistagen (VTGN) Stock Plummets 80% After Phase 3 Trial Failure - Intellectia AI
VISTAGEN ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
VTGN Investors Encouraged to Seek Lead Plaintiff Role in - GlobeNewswire
Buybacks Report: What is the next catalyst for Vistagen Therapeutics IncTrade Performance Summary & Stock Market Timing Techniques - baoquankhu1.vn
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - ACCESS Newswire
Analyst Upgrade: Is Vistagen Therapeutics Inc attractive for institutional investorsJuly 2025 Volume & Long Hold Capital Preservation Tips - baoquankhu1.vn
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionVTGN - ACCESS Newswire
Vistagen Therapeutics Faces Class Action Lawsuit for Securities Fraud - Intellectia AI
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - PR Newswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionVTGN - TMX Newsfile
VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2026-01-19 | VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:VTGN | Press Release - Stockhouse
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, I - GuruFocus
Vistagen Therapeutics Faces Class Action Lawsuit; Investors Encouraged to Claim Losses - Intellectia AI
VTGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionVTGN - TMX Newsfile
Faruqi & Faruqi Investigates Vistagen Investors' Claims Ahead of March 2026 Deadline - Intellectia AI
SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistage - GuruFocus
SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit - PR Newswire
2026-01-18 | VTGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:VTGN | Press Release - Stockhouse
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire
Short Interest in VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Rises By 88.9% - Defense World
VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Cla - GuruFocus
Vistagen Therapeutics (VTGN) Faces Class Action Over Misleading Trial Results, Stock Plummets 80% - Intellectia AI
VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Vistagen Therapeutics, Inc. - PR Newswire
Vistagen Therapeutics Faces Class Action Lawsuit, Shareholders May Claim Compensation - Intellectia AI
Vistagen Therapeutics Faces Class Action Lawsuit for Misleading Investors on Drug Development - Intellectia AI
VTGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Vistagen Therapeutics Inc Azioni (VTGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):